Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kayode Ogungbenro

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|December 8, 2020
PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter-Individual VariabilityHiroyuki Takita, Shelby Barnett, Yueping Zhang, et al.
Journal of Clinical Pharmacology|October 15, 2013
Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: which measure of variability should be used?Farzaneh Salem, Kayode Ogungbenro, Pavan Vajjah, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 13, 2025
Mathematical Modeling of Neuroinflammation in Neurodegenerative DiseasesAlex Foster-Powell, Amin Rostami-Hodjegan, Guy Meno-Tetang, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 19, 2024
Hierarchical cluster analysis and nonlinear mixed-effects modelling for candidate biomarker detection in preclinical models of cancerDavid Hodson, Hitesh Mistry, James Yates, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 11, 2021
Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transportersAmais Ahmad, Kayode Ogungbenro, Annett Kunze, et al.
Clinical Pharmacology and Therapeutics|December 16, 2017
Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and SimulationShelby Barnett, Kayode Ogungbenro, Karelle Ménochet, et al.
The AAPS Journal|January 14, 2022
In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug DispositionYukiko Murata, Sibylle Neuhoff, Amin Rostami-Hodjegan, et al.
The AAPS Journal|February 5, 2020
Global Sensitivity Analysis of the Rodgers and Rowland Model for Prediction of Tissue: Plasma Partitioning Coefficients: Assessment of the Key Physiological and Physicochemical Factors That Determine Small-Molecule Tissue DistributionEstelle Yau, Andrés Olivares-Morales, Michael Gertz, et al.
Journal of Clinical Pharmacology|June 16, 2017
Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and ResistanceBabatunde Ayodeji Adeagbo, Tiwalade Adewale Olugbade, Muheez Alani Durosinmi, et al.
Annals of the Rheumatic Diseases|June 7, 2019
Development and validation of a methotrexate adherence assayJames Bluett, Isabel Riba-Garcia, Suzanne M M Verstappen, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
CPT: Pharmacometrics & Systems Pharmacology|December 8, 2020
PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter-Individual VariabilityHiroyuki Takita, Shelby Barnett, Yueping Zhang, et al.
Journal of Clinical Pharmacology|October 15, 2013
Precision criteria to derive sample size when designing pediatric pharmacokinetic studies: which measure of variability should be used?Farzaneh Salem, Kayode Ogungbenro, Pavan Vajjah, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 13, 2025
Mathematical Modeling of Neuroinflammation in Neurodegenerative DiseasesAlex Foster-Powell, Amin Rostami-Hodjegan, Guy Meno-Tetang, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 19, 2024
Hierarchical cluster analysis and nonlinear mixed-effects modelling for candidate biomarker detection in preclinical models of cancerDavid Hodson, Hitesh Mistry, James Yates, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 11, 2021
Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transportersAmais Ahmad, Kayode Ogungbenro, Annett Kunze, et al.
Clinical Pharmacology and Therapeutics|December 16, 2017
Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and SimulationShelby Barnett, Kayode Ogungbenro, Karelle Ménochet, et al.
The AAPS Journal|January 14, 2022
In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug DispositionYukiko Murata, Sibylle Neuhoff, Amin Rostami-Hodjegan, et al.
The AAPS Journal|February 5, 2020
Global Sensitivity Analysis of the Rodgers and Rowland Model for Prediction of Tissue: Plasma Partitioning Coefficients: Assessment of the Key Physiological and Physicochemical Factors That Determine Small-Molecule Tissue DistributionEstelle Yau, Andrés Olivares-Morales, Michael Gertz, et al.
Journal of Clinical Pharmacology|June 16, 2017
Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and ResistanceBabatunde Ayodeji Adeagbo, Tiwalade Adewale Olugbade, Muheez Alani Durosinmi, et al.
Annals of the Rheumatic Diseases|June 7, 2019
Development and validation of a methotrexate adherence assayJames Bluett, Isabel Riba-Garcia, Suzanne M M Verstappen, et al.
Pageof 10